Non-TNF biologics and their biosimilars in rheumatoid arthritis

References

• Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet Lond Engl. [2017 Jun 10];389(10086):2338–2348. doi: 10.1016/S0140-6736(17)31491-5
   Google Scholar
• Carmona L, Cross M, Williams B, et al. Rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010 Dec;24(6):733–745. doi: 10.1016/j.berh.2010.10.001
   PubMed Web of Science ®Google Scholar
• Mok CC, Kwok CL, Ho LY, et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011 May;63(5):1182–1189. doi: 10.1002/art.30277
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021 Jul;73(7):924–939. doi: 10.1002/acr.24596
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18. doi: 10.1136/ard-2022-223356
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. [2018 Oct 2];320(13):1360–1372. doi: 10.1001/jama.2018.13103
   PubMed Web of Science ®Google Scholar
• Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022 Jun;64:102234. doi: 10.1016/j.coph.2022.102234
   PubMed Web of Science ®Google Scholar
• Song YJ, Nam SW, Suh CH, et al. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview. Expert Opin Drug Metab Toxicol. 2023;19(11):751–768. doi: 10.1080/17425255.2023.2270407
   PubMed Web of Science ®Google Scholar
• Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5(1):e000900. doi: 10.1136/rmdopen-2019-000900
   PubMed Web of Science ®Google Scholar
• Fusaro E, Durez P, Wohlrab J, et al. An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar. Immunotherapy. [2021 Dec 6];14(3):235–252. doi: 10.2217/imt-2021-0271
   Web of Science ®Google Scholar
• Agbogbo FK, Ecker DM, Farrand A, et al. Current perspectives on biosimilars. J Ind Microbiol Biotechnol. 2019 Oct;46(9–10):1297–1311. doi: 10.1007/s10295-019-02216-z
   PubMed Web of Science ®Google Scholar
• Dickson SR, Kent T. Association of generic competition with price decreases in physician-administered drugs and estimated price decreases for biosimilar competition. JAMA Netw Open. [2021 Nov 1];4(11):e2133451. doi: 10.1001/jamanetworkopen.2021.33451
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Nishikawa K, Yamada F, et al. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics. Mod Rheumatol. [2022 Jul 1];32(4):718–727. doi: 10.1093/mr/roab068
   PubMed Web of Science ®Google Scholar
• Graudal N, Kaas-Hansen BS, Guski L, et al. Different original and biosimilar tnf inhibitors similarly reduce joint destruction in rheumatoid arthritis-a network meta-analysis of 36 randomized controlled trials. Int J Mol Sci. [2019 Sep 5];20(18):4350. doi: 10.3390/ijms20184350
   PubMed Web of Science ®Google Scholar
• Bae SC, Lee YH. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials. Int J of Rheum Dis. 2018 May;21(5):922–929. doi: 10.1111/1756-185X.13305
   PubMed Web of Science ®Google Scholar
• Bae SC, Lee YH. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clin Rheumatol. 2018 May;37(5):1199–1205. doi: 10.1007/s10067-018-4002-9
   PubMed Web of Science ®Google Scholar
• Van de Wiele VL, Kesselheim AS, Sarpatwari A. Barriers to US biosimilar market growth: lessons from biosimilar patent litigation. Health Affairs. 2021 Aug;40(8):1198–1205. doi: 10.1377/hlthaff.2020.02484
   Web of Science ®Google Scholar
• Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018 Sep;14(9):739–749. doi: 10.1080/1744666X.2018.1512406
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Franchi G, et al. The Nocebo Effect in Rheumatology: An Unexplored Issue. Isr Med Assoc J IMAJ. 2020 Mar;22(3):185–190.
   PubMed Web of Science ®Google Scholar
• Homepage. European Medicines Agency [Internet]. [cited 2024 May 5]. Available from: https://www.ema.europa.eu/en/homepage
   Google Scholar
• Research C for DE and Biosimilar Product Information. FDA [Internet; 2024 Apr 25 [cited 2024 May 5]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
   Google Scholar
• Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatol Oxf Engl. 2005 May;44(Suppl 2):ii3–7. doi: 10.1093/rheumatology/keh616
   PubMed Web of Science ®Google Scholar
• Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol Baltim Md 1950. 2001 Oct 15;167(8):4710–4718. doi: 10.4049/jimmunol.167.8.4710
   Google Scholar
• Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2010 May;22(3):307–315. doi: 10.1097/BOR.0b013e3283369cb8
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2006 May;6(5 Pt 1):859–866. doi: 10.1111/j.1600-6143.2006.01288.x
   PubMed Web of Science ®Google Scholar
• Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. [2013 Dec 27];8:87–100. doi: 10.2147/DDDT.S41645
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol Oxf Engl. 2001 Feb;40(2):205–211. doi: 10.1093/rheumatology/40.2.205
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May;54(5):1390–1400. doi: 10.1002/art.21778
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatol Oxf Engl. 2010 Sep;49(9):1683–1693. doi: 10.1093/rheumatology/keq116
   PubMed Web of Science ®Google Scholar
• Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010 Sep;69(9):1629–1635. doi: 10.1136/ard.2009.119933
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006 Sep;54(9):2793–2806. doi: 10.1002/art.22025
   PubMed Web of Science ®Google Scholar
• Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011 Jan;70(1):39–46. doi: 10.1136/ard.2010.137703
   PubMed Web of Science ®Google Scholar
• Gerlag DM, Safy M, Maijer KI, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. [2019 Feb 1];78(2):179–185. doi: 10.1136/annrheumdis-2017-212763
   PubMed Web of Science ®Google Scholar
• Abushouk AI, Ahmed H, Ismail A, et al. Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. Rheumatol Int. [2017 Jul 1];37(7):1053–1064. doi: 10.1007/s00296-017-3675-8
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-López AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001 Dec;115(4):807–811. doi: 10.1046/j.1365-2141.2001.03166.x
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Sep;58(9):2652–2661. doi: 10.1002/art.23732
   PubMed Web of Science ®Google Scholar
• Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012 Feb;64(2):350–359. doi: 10.1002/art.33317
   PubMed Web of Science ®Google Scholar
• Stohl W, Gomez-Reino J, Olech E, et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis. 2012 Aug;71(8):1289–1296. doi: 10.1136/annrheumdis-2011-200706
   PubMed Web of Science ®Google Scholar
• Harigai M, Tanaka Y, Maisawa S, et al. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J Rheumatol. 2012 Mar;39(3):486–495. doi: 10.3899/jrheum.110994
   PubMed Web of Science ®Google Scholar
• Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012 Feb;64(2):360–370. doi: 10.1002/art.33353
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol. 2014 Nov;86(5):485–491. doi: 10.1124/mol.114.092684
   PubMed Web of Science ®Google Scholar
• Østergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 2010 Aug;62(8):2227–2238. doi: 10.1002/art.27524
   PubMed Web of Science ®Google Scholar
• Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis. [2011 Dec 1];70(12):2119–2125. doi: 10.1136/ard.2011.151522
   PubMed Web of Science ®Google Scholar
• Pers YM, Jorgensen C. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Immunotherapy. 2016 Sep;8(9):1091–1096. doi: 10.2217/imt-2016-0003
   PubMed Web of Science ®Google Scholar
• Weyand CM, Bryl E, Goronzy JJ. The role of T cells in rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 2000;48(5):429–435.
   PubMedGoogle Scholar
• Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. [2011 Nov 25];11(12):852–863. doi: 10.1038/nri3108
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med. [2006 Jun 20];144(12):865–876. doi: 10.7326/0003-4819-144-12-200606200-00003
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008 Aug;67(8):1096–1103. doi: 10.1136/ard.2007.080002
   PubMed Web of Science ®Google Scholar
• Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011 Oct;63(10):2854–2864. doi: 10.1002/art.30463
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28–38. doi: 10.1002/art.37711
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, et al. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. N Engl J Med. [2005 Sep 15];353(11):1114–1123. doi: 10.1056/NEJMoa050524
   PubMed Web of Science ®Google Scholar
• Bathon J, Robles M, Ximenes AC, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. [2011 Nov 1];70(11):1949–1956. doi: 10.1136/ard.2010.145268
   PubMed Web of Science ®Google Scholar
• Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan;74(1):19–26. doi: 10.1136/annrheumdis-2014-206106
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. [2012 Jun 1];71(6):857–861. doi: 10.1136/annrheumdis-2011-200355
   PubMed Web of Science ®Google Scholar
• Sokolove J, Schiff M, Fleischmann R, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016 Apr;75(4):709–714. doi: 10.1136/annrheumdis-2015-207942
   PubMed Web of Science ®Google Scholar
• Cope AP, Jasenecova M, Vasconcelos JC, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. [2024 Mar 2];403(10429):838–849. doi: 10.1016/S0140-6736(23)02649-1
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet Lond Engl. [2008 Mar 22];371(9617):987–997. doi: 10.1016/S0140-6736(08)60453-5
   Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008 Oct;58(10):2968–2980. doi: 10.1002/art.23940
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. [2008 Nov 1];67(11):1516–1523. doi: 10.1136/ard.2008.092932
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013 Feb;40(2):113–126. doi: 10.3899/jrheum.120447
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88–96. doi: 10.1136/ard.2008.105197
   PubMed Web of Science ®Google Scholar
• Hashimoto J, Garnero P, van der Heijde D, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011 Feb;21(1):10–15. doi: 10.1007/s10165-010-0325-3
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014 Jan;73(1):69–74. doi: 10.1136/annrheumdis-2013-203523
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. [2013 May 4];381(9877):1541–1550. doi: 10.1016/S0140-6736(13)60250-0
   PubMed Web of Science ®Google Scholar
• Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol. 2017 Jun;13(6):535–551. doi: 10.1080/1744666X.2017.1295850
   PubMed Web of Science ®Google Scholar
• Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–1603. doi: 10.2147/DDDT.S100302
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–1437. doi: 10.1002/art.39093
   PubMed Web of Science ®Google Scholar
• Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277–290. doi: 10.1002/art.39944
   PubMed Web of Science ®Google Scholar
• Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. [2017 May 1];76(5):840–847. doi: 10.1136/annrheumdis-2016-210310
   PubMed Web of Science ®Google Scholar
• Genovese MC, van Adelsberg J, Fan C, et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology. [2018 Aug 1];57(8):1423–1431. doi: 10.1093/rheumatology/key121
   PubMed Web of Science ®Google Scholar
• Dörner T, Weinblatt M, Beneden KV, et al. FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. Ann Rheum Dis. [2017 Jun 1];76(Suppl 2):575–575.
   Google Scholar
• Feist E, Fatenejad S, Grishin S, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. [2022 Dec 1];81(12):1661–1668. doi: 10.1136/ard-2022-222630
   PubMed Web of Science ®Google Scholar
• Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. [2022 Aug 25];387(8):715–726. doi: 10.1056/NEJMoa2201302
   PubMed Web of Science ®Google Scholar
• Eskandary F, Dürr M, Budde K, et al. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. [2019 Jan 11];20(1):37. doi: 10.1186/s13063-018-3158-6
   PubMedGoogle Scholar
• Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol Hoboken NJ. 2015 Oct;67(10):2591–2600.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Thorne C, Karpouzas G, et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017 Dec;76(12):2001–2008. doi: 10.1136/annrheumdis-2017-211328
   PubMed Web of Science ®Google Scholar
• Taylor PC, Schiff MH, Wang Q, et al. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis. 2018 May;77(5):658–666. doi: 10.1136/annrheumdis-2017-212496
   PubMed Web of Science ®Google Scholar
• Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet Lond Engl. [2017 Mar 25];389(10075):1206–1217. doi: 10.1016/S0140-6736(17)30401-4
   Google Scholar
• Bartoli F, Bae S, Cometi L, et al. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018. Expert Rev Clin Immunol. [2018 Jul 3];14(7):539–547. doi: 10.1080/1744666X.2018.1487291
   PubMed Web of Science ®Google Scholar
• Aletaha D, Bingham CO, Karpouzas GA, et al. Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD Open. [2021 Feb 1];7(1):e001465. doi: 10.1136/rmdopen-2020-001465
   PubMed Web of Science ®Google Scholar
• Metcalf D. The colony-stimulating factors and cancer. Cancer Immunol Res. 2013 Dec;1(6):351–356. doi: 10.1158/2326-6066.CIR-13-0151
   PubMed Web of Science ®Google Scholar
• Hamilton JA, Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 2013 Feb;34(2):81–89. doi: 10.1016/j.it.2012.08.006
   PubMed Web of Science ®Google Scholar
• Bell AL, Magill MK, McKane WR, et al. Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int. 1995;14(5):177–182. doi: 10.1007/BF00262295
   PubMed Web of Science ®Google Scholar
• Leizer T, Cebon J, Layton JE, et al. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood. [1990 Nov 15];76(10):1989–1996. doi: 10.1182/blood.V76.10.1989.1989
   PubMed Web of Science ®Google Scholar
• Cook AD, Hamilton JA. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. Ther Adv Musculoskelet Dis. [2018 Feb 1];10(2):29–38. doi: 10.1177/1759720X17752036
   PubMed Web of Science ®Google Scholar
• Burmester GR, Feist E, Sleeman MA, et al. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis. 2011 Sep;70(9):1542–1549. doi: 10.1136/ard.2010.146225
   PubMed Web of Science ®Google Scholar
• McInnes IB, Burmester GR, Kremer JM, Miranda P, Korkosz M, Vencovsky J, et al. SAT0189 Rapid onset of clinical benefit in patients with ra treated with mavrilimumab, a fully human monoclonal antibody targeting GM–CSFR-ALPHA: subanalysis of the Phase IIB Earth Explorer 1 Study. Ann Rheum Dis [Internet]. 2015 Jun [cited 2024 Feb 13];74. Suppl 2):723.3–724. Available from: https://www.proquest.com/docview/1901802363/abstract/F771E86D0DB340C8PQ/1
   Google Scholar
• Weinblatt ME, McInnes IB, Kremer JM, et al. A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ. 2018 Jan;70(1):49–59. doi: 10.1002/art.40323
   PubMed Web of Science ®Google Scholar
• Chen BD, Mueller M, Chou TH. Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol Baltim Md 1950. 1988 Jul 1;141(1):139–144. doi: 10.4049/jimmunol.141.1.139
   Google Scholar
• Burmester GR, McInnes IB, Kremer JM, et al. Mavrilimumab, a fully human granulocyte–macrophage colony‐stimulating factor receptor α monoclonal antibody. Arthritis Rheumatol Hoboken NJ. 2018 May;70(5):679–689. doi: 10.1002/art.40420
   PubMed Web of Science ®Google Scholar
• Bykerk VP. The efficacy and safety of targeting GM-CSF in arthritis. Lancet Rheumatol. 2020 Nov;2(11):e648–50. doi: 10.1016/S2665-9913(20)30352-0
   PubMedGoogle Scholar
• Taylor PC, Weinblatt ME, McInnes IB, et al. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRast 3). Ann Rheum Dis. 2023 Dec;82(12):1527–1537. doi: 10.1136/ard-2023-224449
   PubMed Web of Science ®Google Scholar
• Taylor PC, Saurigny D, Vencovsky J, et al. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res Ther. 2019 Dec;21(1):1–13. doi: 10.1186/s13075-018-1791-9
   PubMedGoogle Scholar
• Park W, Božić-Majstorović L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs. 2018;10(6):934–943. doi: 10.1080/19420862.2018.1487912
   PubMed Web of Science ®Google Scholar
• Shim SC, Božić-Majstorović L, Berrocal Kasay A, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatol Oxf Engl. 2019 Dec;58(12):2193–2202. doi: 10.1093/rheumatology/kez152
   PubMed Web of Science ®Google Scholar
• Smolen JS, Cohen SB, Tony HP, et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2017 Sep;76(9):1598–1602. doi: 10.1136/annrheumdis-2017-211281
   PubMed Web of Science ®Google Scholar
• Williams JH, Hutmacher MM, Zierhut ML, et al. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol. 2016 Dec;82(6):1568–1579. doi: 10.1111/bcp.13094
   PubMed Web of Science ®Google Scholar
• Burmester G, Drescher E, Hrycaj P, et al. Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis. Clin Rheumatol. [2020 Nov 1];39(11):3341–3352. doi: 10.1007/s10067-020-05305-y
   PubMed Web of Science ®Google Scholar
• Leng X, Leszczyński P, Jeka S, et al. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial. Lancet Rheumatol. [2024 Jan 1];6(1):e40–50. doi: 10.1016/S2665-9913(23)00237-0
   PubMedGoogle Scholar
• Zubrzycka-Sienkiewicz A, Klama K, Ullmann M, et al. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study. RMD Open. [2024 Feb 1];10(1):e003596. doi: 10.1136/rmdopen-2023-003596
   PubMed Web of Science ®Google Scholar
• Yu KS, Kim B, Shin D, et al. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Expert Opin Investig Drugs. [2023 May 4];32(5):429–439. doi: 10.1080/13543784.2023.2212155
   PubMed Web of Science ®Google Scholar
• Gabi Online. GENERICS and BIOSIMILARS INITIATIVE. 2016 [cited 2024 Feb 16]. Available from: https://www.gabionline.net/biosimilars/general/Biosimilars-of-abatacept
   Google Scholar
• Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016 May;36(5):685–695. doi: 10.1007/s00296-015-3415-x
   PubMed Web of Science ®Google Scholar
• Tan Y, Buch MH. ‘Difficult to treat’ rheumatoid arthritis: current position and considerations for next steps. RMD Open. 2022 Jul;8(2):e002387. doi: 10.1136/rmdopen-2022-002387
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatol Oxf Engl. [2021 Dec 24];60(Suppl 6):vi12–20. doi: 10.1093/rheumatology/keab609
   Google Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs Clin Immunother Biopharm Gene Ther. 2014 Apr;28(Suppl 1):S15–23. doi: 10.1007/s40259-013-0064-z
   Google Scholar
• Carron P, Lambert B, Van Praet L, et al. Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis. RMD Open. 2016;2(1):e000265. doi: 10.1136/rmdopen-2016-000265
   PubMedGoogle Scholar
• Crotti C, Biggioggero M, Becciolini A, et al. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2019 Jul;28(7):573–581. doi: 10.1080/13543784.2019.1631795
   PubMed Web of Science ®Google Scholar
• Shamseldin LS, Shawqi MM, Al Hashem NA, et al. Safety and efficacy of mavrilimumab for rheumatoid arthritis: a systematic review and meta-analysis. Curr Rheumatol Rev. 2021;17(2):184–192. doi: 10.2174/1573397116666201113085444
   PubMed Web of Science ®Google Scholar
• Mortensen JH, Guo X, De Los Reyes M, et al. The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients. Clin Exp Rheumatol. 2019;37(1):73–80.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Kaltsonoudis E, et al. Therapeutic options and cost-effectiveness for rheumatoid arthritis treatment. Curr Rheumatol Rep. [2020 Jun 26];22(8):44. doi: 10.1007/s11926-020-00921-8
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. [2013 Jul 25];369(4):307–318. doi: 10.1056/NEJMoa1303006
   PubMed Web of Science ®Google Scholar